Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes

References

• Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci. 2014;15:13768–13801.
   PubMed Web of Science ®Google Scholar
• Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007;12:327–340.
   PubMed Web of Science ®Google Scholar
• Barnes K, McIntosh E, Whetton AD, et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene. 2005;24:3257–3267.
   PubMed Web of Science ®Google Scholar
• Bentley J, Walker I, McIntosh E, et al. Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model. Br J Haematol. 2001;112:212–215.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–1083.
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
   PubMed Web of Science ®Google Scholar
• Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care. 1997;20:469–471.
   PubMed Web of Science ®Google Scholar
• Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–1737.
   PubMed Web of Science ®Google Scholar
• Rachdi L, El Ghazi L, Bernex F, et al. Expression of the receptor tyrosine kinase KIT in mature beta-cells and in the pancreas in development. Diabetes. 2001;50:2021–2028.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy M, Ayazi F, Li J, et al. c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic beta-cells in c-KitW-v mutant mice. Endocrinology. 2007;148:5520–5530.
   PubMed Web of Science ®Google Scholar
• Cheng H, Straub SG, Sharp GW. Inhibitory role of Src family tyrosine kinases on Ca2+-dependent insulin release. Am J Physiol Endocrinol Metab. 2007;292:E845–E852.
   PubMed Web of Science ®Google Scholar
• Veneri D, Franchini M, Bonora E, Imatinib and regression of type 2 diabetes. N Engl J Med. 2005;352:1049–1050.
   PubMed Web of Science ®Google Scholar
• Folli F, Galimberti G, Pastore M, et al. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate. Diabetes Care. 2006;29:2178–2180.
   PubMed Web of Science ®Google Scholar
• Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17:197–202.
   PubMedGoogle Scholar
• Breccia M, Muscaritoli M, Aversa Z, et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22:4653–4655.
   PubMed Web of Science ®Google Scholar
• Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract. 2007;13:126–130.
   PubMedGoogle Scholar
• Chodorowski Z, Sein Anand J, Hellmann A, et al. [No influence of imatinib on type 2 diabetes]. Przegl Lek. 2007;64:370–371.
   PubMedGoogle Scholar
• Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6:33944–33951.
   PubMed Web of Science ®Google Scholar
• Larson RA, Kim D-W, Issaragrilsil S, et al. Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In: American Society of Hematology Meeting; San Francisco (CA); 2014.
   Google Scholar
• Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2008;99:1380–1382.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Cannella L, et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32:1626–1628.
   PubMed Web of Science ®Google Scholar
• Ono K, Suzushima H, Watanabe Y, et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern Med. 2012;51:2763–2766.
   PubMed Web of Science ®Google Scholar
• Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care. 2006;29:1711.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamoto T, Chong Y, et al. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013;97:135–138.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31:1770–1772.
   PubMed Web of Science ®Google Scholar
• Huda MS, Amiel SA, Ross P, et al. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014;37:e87–e88.
   PubMed Web of Science ®Google Scholar
• Templeton A, Brandle M, Cerny T, et al. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824–825.
   PubMed Web of Science ®Google Scholar
• Han MS, Chung KW, Cheon HG, et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes. 2009;58:329–336.
   PubMed Web of Science ®Google Scholar
• Prada PO, Ropelle ER, Mourao RH, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009;58:2910–2919.
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Jansson L, Welsh N, Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond). 2008;114:65–71.
   PubMed Web of Science ®Google Scholar
• Lim YM, Lim H, Hur KY, et al. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. Nat Commun. 2014;5:4934.
   PubMed Web of Science ®Google Scholar
• Mokhtari D, Al-Amin A, Turpaev K, et al. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5ʹ-phosphatase interaction with c-Abl. Diabetologia. 2013;56:1327–1338.
   PubMed Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105:18895–18900.
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Makeeva N, Elliman S, et al. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int. 2006;30:1013–1017.
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Sandler S, Mokhtari D, et al. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. Faseb J. 2007;21:618–628.
   PubMed Web of Science ®Google Scholar
• Mokhtari D, Li T, Lu T, et al. Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6:e24831.
   PubMed Web of Science ®Google Scholar
• Xia CQ, Zhang P, Li S, et al. C-Abl inhibitor imatinib enhances insulin production by beta cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One. 2014;9:e97694.
   PubMed Web of Science ®Google Scholar
• Szalek E, Karbownik A, Sobanska K, et al. The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacol Rep. 2014;66:892–896.
   PubMed Web of Science ®Google Scholar
• Lassila M, Allen TJ, Cao Z, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:935–942.
   PubMed Web of Science ®Google Scholar
• Oh JJ, Hong SK, Joo YM, et al. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42:314–317.
   PubMed Web of Science ®Google Scholar
• Fitter S, Vandyke K, Schultz CG, et al. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95:3763–3767.
   PubMed Web of Science ®Google Scholar
• Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med. 1974;43:339–357.
   PubMedGoogle Scholar